MaxCyte, Inc. (MXCT)

MaxCyte's stock price has significantly declined, with a 74.96% decrease between March 31, 2025, and March 27, 2026. Key events include the November 2025 report of preliminary third-quarter results showing revenue declines, the February 2026 unveiling of the ExPERT DTx platform, and the March 2026 report of fourth-quarter and full-year 2025 financial results, which also showed revenue decreases. The company's full-year 2026 revenue guidance was below consensus, impacted by headwinds from SPL customers. Craig-Hallum lowered its price target, and Parmeet Ahuja was appointed as Chief Financial Officer.

MaxCyte exhibits seasonal tendencies, with July historically being the strongest month and August the weakest. The company's ability to forecast customer demand and manage inventory is crucial. Its business model includes recurring revenue from various sources, providing some visibility into long-term revenue generation.

MaxCyte, Inc. is a cell-engineering focused life sciences company advancing cell therapeutics through its Flow Electroporation technology. It operates in the biotechnology and pharmaceutical industries, focusing on the healthcare sector. Its core business revolves around its Flow Electroporation platform, which facilitates the efficient and precise non-viral delivery of molecules into cells, crucial for cell therapy research, development, and manufacturing. Major products include the ExPERT platform, comprising the ATx, STx, GTx, and VLx instruments. Revenue is generated through instrument sales, reagents, disposables, and licensing agreements. In January 2025, MaxCyte acquired SeQure Dx, a market leader for on-target and off-target editing assessment services.

MaxCyte is headquartered in Gaithersburg, Maryland, with a corporate office in Rockville, Maryland, and maintains a global presence with offices and service centers across North America, Europe, and Asia. It serves a global client base, including academic institutions, biopharmaceutical companies, and CDMOs.

MaxCyte is recognized as a leading cell-engineering company with expertise in Flow Electroporation technology. Its technology enables non-viral delivery with high efficiency, viability, and scalability. However, recent financial performance, including revenue declines and lowered guidance, has negatively impacted its reputation among investors, leading to a stock price drop and price target reduction, despite analysts maintaining an average "Hold" rating.

MaxCyte has 118 institutional owners and shareholders holding a total of 62,383,576 shares. Institutions hold approximately 74.5% of the shares, while the general public holds about 24.5%, and individual insiders hold around 1.06%. Major institutional owners include BlackRock, Inc., Mirabella Financial Services LLP, and The Vanguard Group, Inc.